Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Lingo01:11

Genetic Lingo

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Break Down of the Complexity and Inconsistency Between Levels of Matriglycan and Disease Phenotype in FKRP-Related Dystroglycanopathies: A Review and Model of Interpretation.

Journal of neuromuscular diseases·2024
Same author

Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.

Molecular therapy : the journal of the American Society of Gene Therapy·2023
Same author

Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model.

PloS one·2022
Same author

ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice.

Molecular therapy. Methods & clinical development·2020
Same author

Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.

Nature communications·2018
Same author

Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo- mouse model of FKRP-deficient muscular dystrophy.

Skeletal muscle·2018

Related Experiment Video

Updated: May 10, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.8K

Ribitol treatment rescues dystroglycanopathy mice with common L276I mutation.

Bo Wu1, Pei Juan Lu1, Morgan Drains1

  • 1McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Carolinas Medical Center, Charlotte, North Carolina, United States of America.

Plos One
|August 20, 2025
PubMed
Summary

Ribitol treatment effectively restores matriglycan in muscles affected by FKRP mutations, showing promise for treating dystroglycanopathies like LGMD2I/R9.

More Related Videos

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.9K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

18.8K

Related Experiment Videos

Last Updated: May 10, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.8K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.9K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

18.8K

Area of Science:

  • Biochemistry
  • Genetics
  • Muscle Biology

Background:

  • Matriglycan, a key component of alpha-dystroglycan (α-DG), is essential for muscle integrity.
  • Defects in matriglycan synthesis due to FKRP gene mutations cause dystroglycanopathies, a group of muscular dystrophies.
  • Ribitol can partially restore matriglycan but its efficacy depends on residual FKRP function.

Purpose of the Study:

  • To evaluate the long-term efficacy of ribitol in restoring matriglycan in a mouse model with the common FKRP C826A (L276I) mutation.
  • To assess the impact of ribitol treatment on muscle pathology and function in these mice.

Main Methods:

  • Oral administration of ribitol to mice with the FKRP L276I mutation.
  • Quantification of matriglycan expression in cardiac and skeletal muscles.
  • Histological analysis of muscle degeneration, regeneration, fibrosis, and central nucleation.
  • Assessment of muscle function.

Main Results:

  • Ribitol treatment significantly enhanced matriglycan expression (up to 40% of normal) homogeneously across muscle fibers, particularly in cardiac muscle.
  • Muscle degeneration, regeneration, fibrosis, and central nucleation were markedly reduced, especially in the diaphragm.
  • Improvements in muscle function were observed, correlating with enhanced matriglycan levels.
  • Higher restoration in L276I mice compared to P448L mice supports the role of residual FKRP function.

Conclusions:

  • Ribitol is a promising therapeutic agent for dystroglycanopathies caused by FKRP mutations, including the common L276I genotype.
  • The degree of matriglycan restoration and therapeutic benefit appears dependent on the residual function of mutant FKRP proteins.
  • These findings support the initiation of clinical trials for ribitol treatment in patients with FKRP-related muscular dystrophies.